In a phase 1b/2 trial, an off-the-shelf vaccine using gorilla adenoviral and modified vaccinia Ankara vectors with over 200 mutated peptides known to be present in persons with mismatch-repair-deficie...

Ask AI-powered questions about gastroenterology and enhance your academic learning.

Abstract Peptide presentation on human leukocyte antigens (HLAs) is essential for initiating T-cell responses and all consequences of this presentation including anticancer immunity or immune escape. ...

New clinical trial aims to use whole, light-inactivated tumor cells for immunotherapy

Here the authors show DNGR-1 expressed by cDC1s promotes CD8⁺ T cell priming to cytoskeletal neoantigens from dying tumor cells, thereby shaping cancer immune visibility and tumor evolution through im...

Here the authors show DNGR-1 expressed by cDC1s promotes CD8⁺ T cell priming to cytoskeletal neoantigens from dying tumor cells, thereby shaping cancer immune visibility and tumor evolution through im...

The secreted gelsolin component of the plasma actin-scavenging system impairs the ability of the receptor DNGR-1 to recognize dead cells and selectively dampens cross-presentation of tumor antigens by...

Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move beyond one-time attacks and short-term memory to become a long-term immunity that "remembers" cancer, effectively preventing recurrence.

Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move beyond one-time attacks and short-term memory to become a long-term immunity that "remembers" cancer, effectively preventing recurrence. KAIST's research team has developed an AI-based personalized cancer vaccine design technology that makes this possible and optimizes anticancer effects for each individual.

Ishino et al. combined immunopeptidomics with full-length transcriptomics and revealed various HLA-presented peptides, including those undetectable by conventional approaches. By validating the reactivity of specific TCRs, they uncovered multiple neoantigen-TCR pairs, expanding the current understanding of neoantigen diversity.

Ma et al. performed a multiple-omics analysis of 166 glioma patients and proposed the MINER pipeline for discovering canonical and non-canonical neoantigens. Neoantigen burden analysis improves patient stratification and potentiates combination immunotherapy for glioma.

Immunotherapy represents a promising strategy for cancer treatment that utilizes immune cells or drugs to activate the patient’s own immune system and eliminate cancer cells. One of the most exciting ...